EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study

Yingying Shen, Qi Liu, Hangchao Li, Wenbin Liu, Huijin Hu, Yuechao Zhao, Yuzhu Li, Ying Chen, Shan Liu, Qinghong Yu, Haifeng Zhuang, Liqiang Wu und 8 weitere

Annals of Hematology · 2023

DOI: 10.1007/s00277-023-05086-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2023. Verfasst von Yingying Shen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, #54 Youdian Road, Hangzhou, 310006, Zhejiang, China. Hauptthemen laut MEDLINE: Anemia, Aplastic, Pancytopenia, Fanconi Anemia Complementation Group Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Scientific Research Fund of Traditional Chinese Medicine, Health technology Plan of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired aplastic anemia (AA) is a bone marrow failure disorder characterized by pancytopenia, and immunosuppressive therapy (IST) is the optional first-line management. Several studies identified the influencing factors on IST response; however, there are still a considerable number of patients suffering from poor prognoses. In this study, we enrolled 61 AA patients aged ≤ 40 years old, and whole-exome sequencing (WES) found unexpected high FANC heterozygous germline mutations (28/61, 45.9%). Patients with FANC mutations have a significantly lower absolute reticulocyte count and CD34 + % in the bone marrow and also lower 3-, 6-, and 9-month IST response than that without mutation, which were 0% vs. 25% ( P = 0.017), 26.3% vs. 42.1% ( P = 0.495), and 29.4% vs. 72.2% ( P = 0.011), especially in anti-thymocyte globulin combined with the cyclosporin A (ATG + CsA) group, which were 0% vs.33.4% ( P = 0.143), 25% vs.83.3% ( P = 0.103), and 25% vs. 100% ( P = 0.003), respectively. The event-free survival in the FANC wt group was also better than that in the FANC mut group ( P = 0.016) and also showed in patients who received ATG + CsA treatment ( P = 0.045). In addition, all the adverse effects of FANC germline mutation were not significant in stem cell–transplanted group. Our result indicated that the WES-based detection of FANC heterozygous germline mutations may have a great meaning in predicting IST response of acquired AA. This study was registered at chictr.org.cn (# ChiCTR2100054992).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, AplasticPancytopeniaFanconi Anemia Complementation Group ProteinsAdultHumansAntilymphocyte SerumCyclosporineEast Asian PeopleExome SequencingGerm-Line MutationImmunosuppression TherapyImmunosuppressive AgentsRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Acquired aplastic anemiaFANCGermline mutationHematopoietic stem cell transplantationImmunosuppressive therapy

Substanzen

Antilymphocyte SerumCyclosporineImmunosuppressive AgentsFanconi Anemia Complementation Group Proteins

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, #54 Youdian Road, Hangzhou, 310006, Zhejiang, China.
  • National TCM Clinical Research Base (Hematology), Hangzhou, Zhejiang, China.
  • The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Department of Clinical Evaluation Center, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University, #54 Youdian Road, Hangzhou, 310006, Zhejiang, China. 13588453501@163.com.
  • National TCM Clinical Research Base (Hematology), Hangzhou, Zhejiang, China. 13588453501@163.com.

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Scientific Research Fund of Traditional Chinese Medicine
  • Health technology Plan of Zhejiang Province

Zitieren

APA

Shen, Y., Liu, Q., Li, H., Liu, W., Hu, H., Zhao, Y., Li, Y., Chen, Y., Liu, S., Yu, Q., Zhuang, H., Wu, L., Hu, Z., Zheng, Z., Shen, J., Lin, S., Shen, Y., Zhou, Y., Ye, B., & Wu, D. (2023). Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study. Annals of Hematology. https://doi.org/10.1007/s00277-023-05086-9

Vancouver

Shen Y, Liu Q, Li H, Liu W, Hu H, Zhao Y, et al. Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study. Annals of Hematology. 2023. doi:10.1007/s00277-023-05086-9

BibTeX
@article{Shen2023,
  author = {Shen, Yingying and Liu, Qi and Li, Hangchao and Liu, Wenbin and Hu, Huijin and Zhao, Yuechao and Li, Yuzhu and Chen, Ying and Liu, Shan and Yu, Qinghong and Zhuang, Haifeng and Wu, Liqiang and Hu, Zhiping and Zheng, Zhiyin and Shen, Jianping and Lin, Shenyun and Shen, Yiping and Zhou, Yuhong and Ye, Baodong and Wu, Dijiong},
  title = {Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study},
  journal = {Annals of Hematology},
  year = {2023},
  doi = {10.1007/s00277-023-05086-9}
}
Kostenlos starten →